Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.
Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores
Yolanda Jerez Gilarranz
Breast cancer accounts for 30% of all tumors. Current incidence rates are high, and the estimated lifetime risk for women is 12.5% (i.e., 1 in 8 women will be diagnosed with cancer of the breast during their lifetime). Classically, breast cancer has been divided into two subgroups, which have different outcomes and prognoses depending on their response to hormone therapy (sensitive and insensitive). Other traditional prognostic markers include axillary lymph node status, tumor size, nuclear grade and histological grade. In the last decade, new technologies for analyzing the genomic profiles of human tumors have substantially improved our knowledge of the molecular classification of breast cancer. This development improves diagnostic accuracy and enhances the ability to individualize therapy for breast cancer, thereby leading to direct implications for patient management.